Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies designed to “reboot” the body’s innate immune system, has just published collaborative research with Dartmouth College detailing the mechanism of action and efficacy of Qu’s lung-targeted SSI, QBKPN, for the treatment of lung cancer. It has long been recognized that acute infection can potentially trigger the…
Read More
The VERO study is the first properly designed and powered clinical trial comparing antiresorptive with bone anabolic therapy with fracture as the primary endpoint. Although it makes intuitive sense to first build bone and then preserve improved bone strength, the cost as well as the lack of proven anti-fracture superiority has led to the underutilization of bone anabolic therapy...
Read More
Tommy Douglas. Terry Fox. Michael Bliss. Judith Hall. These renowned individuals are among the 125 laureates of the Canadian Medical Hall of Fame(CMHF), which recognizes Canadian heroes whose work has advanced health. Established in 1994, the national charitable organization aims to inspire pursuit of careers in the health sciences, while celebrating the country’s rich medical history. In April of 2018, an induction ceremony will see Canadian…
Read More
As part of its Industry Innovation Program (I² Fund), Genome BC is investing CAD $750,000 in a local microbiome testing company—Vancouver-based Microbiome Insights (MBI), which provides next-generation-sequencing-based analytical testing and consulting services to microbiome researchers in academia and industry. The new funding adds to the company’s recent round of equity financing, which closed in October. Microbiomes are the communities of…
Read More
We are interested in developing enrichment or cultivation approaches needed to directly test the hypotheses proposed in the manuscript. We also want to integrate our findings into a recently developed pathway-centric numerical model describing coupled biogeochemical cycling in the Saanich Inlet water column. We use Saanich Inlet as a model ecosystem for studying microbial community...
Read More
Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies designed to “reboot” the body’s innate immune system, has just published collaborative research with Dartmouth College detailing the mechanism of action and efficacy of Qu’s lung-targeted SSI, QBKPN, for the treatment of lung cancer. It has long been recognized that acute infection can potentially trigger the…
Read More

Revving Your Nanoscale Engine

Biological molecular machines are microscopic proteins that carry out biological tasks by converting between different forms of energy. Many molecular machines burn chemical fuel to produce movement, similar to a car engine, only 100 million times smaller. An example of this is the protein kinesin, which transports cargo along cellular filaments to specific destinations within cells, and supports critical functions such…
Read More
Canada’s talented and skilled workforce is a competitive advantage for our country that attracts investment, drives innovation, and strengthens the economy. That’s why our government is investing in Canadians—to make sure our students and recent graduates have the skills they need for the middle-class jobs of today and tomorrow. The Honourable Navdeep Bains, Minister of Innovation, Science and Economic Development,…
Read More
In this paper we have generated and characterized a mouse model for Stargardt disease in which the conserved asparagine residue at position 965 in an ATP-binding binding domain of ABCA4 is replaced with serine. This disease-associated missense mutation (N965S) is commonly found in the European and Asian population and a similar mutation in a related transporter ABCA1...
Read More
Regulatory T cells (Tregs) are potent suppressors of immune responses and are currently being clinically tested for their potential to stop or control undesired immune responses in autoimmunity, hematopoietic stem cell transplantation, and solid organ transplantation. Current clinical approaches aim to boost Tregs in vivo either by using Treg-promoting small molecules/proteins and/or by adoptive transfer of expanded Tregs. However, the applicability of…
Read More